Efficacy and Safety of GutGard ® in Managing Gastroesophageal Reflux-Related Symptoms: A Phase III, Single-Centre, Double-Blind, Randomized Placebo-Controlled Trial
Complementary Medicine Research · 2025
DOI: 10.1159/000543367 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Complementary Medicine Research, 2025. Verfasst von Jeffrey Pradeep Raj und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Pharmacology, Kasturba Medical College Manipal, Manipal Academy of Higher Education (MAHE), Manipal,…. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Plant Extracts, Glycyrrhiza. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Liquorice (Glycyrrhiza glabra) is a traditional herbal remedy with various pharmacological activities mainly used for digestive and respiratory ailments. GutGard® is a flavonoid-rich, deglycyrrhizinated liquorice root extract and is standardized to glabridin (≥3.5% w/w), and others viz., glabrol, eicosanyl caffeate, docosyl caffeate, and total flavonoids (≥10% w/w) with glycyrrhizin (≤3.0% w/w) as glycyrrhizin causes electrolyte imbalance, hypertension, and water retention. Hence, the objective of the current study was to assess the efficacy, safety, and tolerability of GutGard® in managing gastroesophageal reflux (GER)-related symptoms when compared to placebo.
Methods
It was a double-blind, parallel group, randomized, placebo-controlled trial with participants randomized in a 1:1 ratio to either the placebo group or GutGard® group. The duration of the interventions/treatment was for 28 days and the follow-up visits were done at day 7, day 14, day 28, and day 35. A telephonic follow-up was also done on day 21. The primary outcome measures studied was the change in the Gastroesophageal Reflux Disease-Health-Related Quality of Life and the Gastroesophageal Reflux Disease Symptom Assessment Scale.
Results
We screened a total of n = 296 participants and enrolled n = 200 participants and obtained written, informed consent from them. Participants in the GutGard® group reported a significantly better quality of life at the end of the intervention period (p = 0.014). They also reported earlier resolution of symptoms of GER as against the placebo group, especially the symptoms of heartburn (p = 0.017 on day 14 and p = 0.005 on day 28) and regurgitation (p = 0.025 on day 7, p = 0.029 on day 14, and p = 0.022 on day 28).
Conclusions
The GutGard® group showed better and earlier resolution (within 2 weeks) of symptoms of GER as against the placebo group, especially heartburn and regurgitation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Pharmacology, Kasturba Medical College Manipal, Manipal Academy of Higher Education (MAHE), Manipal, India.
- Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, India.
- Department of Gastroenterology, Seth GS Medical College and KEM Hospital, Mumbai, India.
- Department of Nuclear Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India.
Zitieren
APA
Raj, J. P., Saxena, U., Belhekar, M. N., Mamde, A., Darak, H., & Pawar, S. (2025). Efficacy and Safety of GutGard ® in Managing Gastroesophageal Reflux-Related Symptoms: A Phase III, Single-Centre, Double-Blind, Randomized Placebo-Controlled Trial. Complementary Medicine Research. https://doi.org/10.1159/000543367
Vancouver
Raj JP, Saxena U, Belhekar MN, Mamde A, Darak H, Pawar S. Efficacy and Safety of GutGard ® in Managing Gastroesophageal Reflux-Related Symptoms: A Phase III, Single-Centre, Double-Blind, Randomized Placebo-Controlled Trial. Complementary Medicine Research. 2025. doi:10.1159/000543367
BibTeX
@article{Raj2025,
author = {Raj, Jeffrey Pradeep and Saxena, Unnati and Belhekar, Mahesh Namdeo and Mamde, Ambika and Darak, Harish and Pawar, Shwetal},
title = {Efficacy and Safety of GutGard ® in Managing Gastroesophageal Reflux-Related Symptoms: A Phase III, Single-Centre, Double-Blind, Randomized Placebo-Controlled Trial},
journal = {Complementary Medicine Research},
year = {2025},
doi = {10.1159/000543367}
}
EUVIMED